Your browser doesn't support javascript.
loading
Chemometrics in Protein Formulation: Stability Governed by Repulsion and Protein Unfolding.
Kulakova, Alina; Augustijn, Dillen; El Bialy, Inas; Gentiluomo, Lorenzo; Greco, Maria Laura; Hervø-Hansen, Stefan; Indrakumar, Sowmya; Mahapatra, Sujata; Martinez Morales, Marcello; Pohl, Christin; Polimeni, Marco; Roche, Aisling; Svilenov, Hristo L; Tosstorff, Andreas; Zalar, Matja; Curtis, Robin; Derrick, Jeremy P; Frieß, Wolfgang; Golovanov, Alexander P; Lund, Mikael; Nørgaard, Allan; Khan, Tarik A; Peters, Günther H J; Pluen, Alain; Roessner, Dierk; Streicher, Werner W; van der Walle, Christopher F; Warwicker, Jim; Uddin, Shahid; Winter, Gerhard; Bukrinski, Jens Thostrup; Rinnan, Åsmund; Harris, Pernille.
Afiliación
  • Kulakova A; Department of Chemistry, Technical University of Denmark, Kemitorvet 207, Kongens, Lyngby 2800, Denmark.
  • Augustijn D; Department of Food Science, Faculty of Science, University of Copenhagen, Rolighedsvej 26, Frederiksberg 1958, Denmark.
  • El Bialy I; Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universitaet Muenchen, Butenandtstrasse 5, Munich 81377, Germany.
  • Gentiluomo L; Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universitaet Muenchen, Butenandtstrasse 5, Munich 81377, Germany.
  • Greco ML; Wyatt Technology Europe GmbH, Hochstrasse 18, Dernbach 56307, Germany.
  • Hervø-Hansen S; Dosage Form Design and Development, AstraZeneca, Sir Aaron Klug Building, Granta Park, Cambridge CB21 6GH, U.K.
  • Indrakumar S; Division of Theoretical Chemistry, Department of Chemistry, Lund University, P.O. Box 124, Lund 22100, Sweden.
  • Mahapatra S; Department of Chemistry, Technical University of Denmark, Kemitorvet 207, Kongens, Lyngby 2800, Denmark.
  • Martinez Morales M; Novozymes A/S, Krogshoejvej 36, Bagsvaerd 2880, Denmark.
  • Pohl C; Dosage Form Design and Development, AstraZeneca, Sir Aaron Klug Building, Granta Park, Cambridge CB21 6GH, U.K.
  • Polimeni M; Novozymes A/S, Krogshoejvej 36, Bagsvaerd 2880, Denmark.
  • Roche A; Division of Theoretical Chemistry, Department of Chemistry, Lund University, P.O. Box 124, Lund 22100, Sweden.
  • Svilenov HL; Department of Chemical Engineering, Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester M1 7DN, U.K.
  • Tosstorff A; Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universitaet Muenchen, Butenandtstrasse 5, Munich 81377, Germany.
  • Zalar M; Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universitaet Muenchen, Butenandtstrasse 5, Munich 81377, Germany.
  • Curtis R; Department of Chemistry, School of Natural Sciences, Faculty of Science and Engineering, and Manchester Institute of Biotechnology, The University of Manchester, Oxford Road, Manchester M13 9PL, U.K.
  • Derrick JP; Department of Chemical Engineering, Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester M1 7DN, U.K.
  • Frieß W; School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Oxford Road, Manchester M13 9PT, U.K.
  • Golovanov AP; Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universitaet Muenchen, Butenandtstrasse 5, Munich 81377, Germany.
  • Lund M; Department of Chemistry, School of Natural Sciences, Faculty of Science and Engineering, and Manchester Institute of Biotechnology, The University of Manchester, Oxford Road, Manchester M13 9PL, U.K.
  • Nørgaard A; Division of Theoretical Chemistry, Department of Chemistry, Lund University, P.O. Box 124, Lund 22100, Sweden.
  • Khan TA; Novozymes A/S, Krogshoejvej 36, Bagsvaerd 2880, Denmark.
  • Peters GHJ; Pharmaceutical Development & Supplies, Pharma Technical Development Biologics Europe, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel 4070, Switzerland.
  • Pluen A; Department of Chemistry, Technical University of Denmark, Kemitorvet 207, Kongens, Lyngby 2800, Denmark.
  • Roessner D; Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, U.K.
  • Streicher WW; Wyatt Technology Europe GmbH, Hochstrasse 18, Dernbach 56307, Germany.
  • van der Walle CF; Novozymes A/S, Krogshoejvej 36, Bagsvaerd 2880, Denmark.
  • Warwicker J; Dosage Form Design and Development, AstraZeneca, Sir Aaron Klug Building, Granta Park, Cambridge CB21 6GH, U.K.
  • Uddin S; School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Oxford Road, Manchester M13 9PT, U.K.
  • Winter G; Dosage Form Design and Development, AstraZeneca, Sir Aaron Klug Building, Granta Park, Cambridge CB21 6GH, U.K.
  • Bukrinski JT; Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universitaet Muenchen, Butenandtstrasse 5, Munich 81377, Germany.
  • Rinnan Å; CMCAssist ApS, Ole Maaløes Vej 3, Copenhagen N 2200, Denmark.
  • Harris P; Department of Food Science, Faculty of Science, University of Copenhagen, Rolighedsvej 26, Frederiksberg 1958, Denmark.
Mol Pharm ; 20(6): 2951-2965, 2023 06 05.
Article en En | MEDLINE | ID: mdl-37146162
ABSTRACT
Therapeutic proteins can be challenging to develop due to their complexity and the requirement of an acceptable formulation to ensure patient safety and efficacy. To date, there is no universal formulation development strategy that can identify optimal formulation conditions for all types of proteins in a fast and reliable manner. In this work, high-throughput characterization, employing a toolbox of five techniques, was performed on 14 structurally different proteins formulated in 6 different buffer conditions and in the presence of 4 different excipients. Multivariate data analysis and chemometrics were used to analyze the data in an unbiased way. First, observed changes in stability were primarily determined by the individual protein. Second, pH and ionic strength are the two most important factors determining the physical stability of proteins, where there exists a significant statistical interaction between protein and pH/ionic strength. Additionally, we developed prediction methods by partial least-squares regression. Colloidal stability indicators are important for prediction of real-time stability, while conformational stability indicators are important for prediction of stability under accelerated stress conditions at 40 °C. In order to predict real-time storage stability, protein-protein repulsion and the initial monomer fraction are the most important properties to monitor.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Quimiometría / Anticuerpos Monoclonales Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mol Pharm Asunto de la revista: BIOLOGIA MOLECULAR / FARMACIA / FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Quimiometría / Anticuerpos Monoclonales Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mol Pharm Asunto de la revista: BIOLOGIA MOLECULAR / FARMACIA / FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca